PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY
Orgo-Life the new way to the future Advertising by AdpathwayA narrative review published in Clinical and Experimental Medicine reveals that rabbit anti-T-lymphocyte globulin (ATLG; Grafalon) and rabbit anti-thymocyte globulin (ATG; Thymoglobulin) are noninterchangeable polyclonal preparations with unresolved dosing strategies when paired with post-transplant cyclophosphamide (PTCy) in haploidentical hematopoietic cell transplantation (haplo-HCT). Although both agents are widely used across haploidentical transplantation platforms, their primary immunogens, active antibody repertoires, and nominal dose scales differ fundamentally. Despite these substantial biochemical and pharmacological distinctions, direct comparative clinical evidence between the two rabbit globulin formulations remains sparse.
The review emphasizes that the limited available comparative clinical literature cannot establish intrinsic therapeutic differences between the products. Specifically, an existing propensity-matched haploidentical transplant comparison evaluated Thymoglobulin administered at 6 mg/kg against ATLG administered at 10 mg/kg. However, the 10 mg/kg dosage of ATLG was substantially lower than the cumulative totals commonly delivered even in matched-donor transplantation settings. Consequently, observed outcomes regarding post-transplant infection rates and chronic graft-versus-host disease in that comparison reflect dose disparities rather than true biological differences between the formulations.
Currently, serotherapy-based and PTCy-based transplantation platforms continue to coexist worldwide, including at transplant centers outside Western countries. Despite their widespread concurrent application, clinical trials have not established either the optimal rabbit-globulin dose or the optimal PTCy dose within combined prophylaxis regimens. Active-antibody exposure varies widely among recipients and is significantly modified by physiological and procedural variables, most notably the recipient absolute lymphocyte count (ALC), the exact timing of globulin infusion, and overall graft cellularity.
While ATLG-specific absolute lymphocyte count investigations corroborate the link between circulating lymphocytes and antibody exposure, prospectively validated ALC-based dosing models for ATLG remain an unmet need in the field. The authors conclude that rabbit globulin products, conditioning regimens, donor graft sources, PTCy dosing, mycophenolate mofetil, and accompanying immunosuppressive agents must be assessed as an integrated protocol. Until dedicated clinical trials determine precise exposure targets and quantify the net clinical benefit of combination prophylaxis, clinical administration should adhere to product-specific, locally validated regimens.
Subject of Research: Comparative evidence and dosing of rabbit polyclonal globulins in haploidentical transplantation
Article Title: Rabbit ATLG and thymoglobulin in haploidentical hematopoietic cell transplantation product specific evidence and unresolved dosing with PTCy
Article References: Wang, Y., & Xiao, Y. (2026). Rabbit ATLG and thymoglobulin in haploidentical hematopoietic cell transplantation product specific evidence and unresolved dosing with PTCy. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-026-02395-x
Image Credits: AI Generated
DOI: 10.1007/s10238-026-02395-x
Keywords: rabbit ATLG, Thymoglobulin, Grafalon, haploidentical hematopoietic cell transplantation, post-transplant cyclophosphamide, PTCy, serotherapy, polyclonal preparations, chronic graft-versus-host disease, absolute lymphocyte count, graft cellularity, mycophenolate mofetil, combination prophylaxis, active-antibody exposure, matched-donor transplantation, infusion timing


7 hours ago
10




















English (US) ·
French (CA) ·